Advanced search
Publication Cover
Cancer Investigation Volume 24, 2006 - Issue 3
Submit an article Journal homepage
71
Views
10
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

A Phase II Study of Doxorubicin, Cisplatin, and 5-Fluorouracil in Patients with Advanced Adenocarcinoma of the Stomach or Esophagus

Matthew H. Kulke Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
, M.D.,
Bingyan Wu Department of Biostatistics, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
, M.S.,
Jeffrey W. Clark Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
, M.D.,
Peter C. Enzinger Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
, M.D.,
Thomas J. Lynch Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
, M.D.,
Michele Vincitore Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
, B.S.,
Ann Michelini Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
, RN, MSN &
Charles S. Fuchs Channing Laboratory, Brigham and Women's Hospital, Boston, Massachusetts, USA
, M.D., MPH show all
Pages 229-234 | Published online: 11 Jun 2009

REFERENCES

  • Devesa S., Blot W., Frangioni J. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2049–2053, [INFOTRIEVE], [CSA]
  • Jemal A., Tiwari R., Murray T., et al. Cancer Statistics, 2004. CA Cancer J. Clinicians 2004; 54: 8–29, [CSA]
  • Murad A., Santiago F., Petroianu A., Rocha P., Rodrigues M., et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993; 72: 37–41, [INFOTRIEVE], [CSA]
  • Pyrhonen S., Kuitunen T., Nyandoto P., Kouri M. Randomised comparison of fluorouracil, epidoxorubicin, and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br. J. Cancer 1995; 71: 587–591, [INFOTRIEVE], [CSA]
  • Glimelius B., Ekstrom K., Hoffman K., et al. Randomised comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann. Oncol. 1997; 8: 163–168, [INFOTRIEVE], [CROSSREF], [CSA]
  • Wils J., Klein H., Wagener D., et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin: a step ahead in the treatment of advanced gastric cancer: a trial of the EORTC Gastrointestinal Tract Cooperative Group. J. Clin. Oncol. 1991; 9: 827–831, [PUBMED], [INFOTRIEVE], [CSA]
  • Vanhoefer U., Rougier P., Wilke H., et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J. Clin. Oncol. 2000; 18: 2648–2657, [PUBMED], [INFOTRIEVE], [CSA]
  • Findlay M., Cunningham D., Norman A., et al. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann. Oncol. 1994; 5: 609–616, [INFOTRIEVE], [CSA]
  • Webb A., Cunningham D., Scarffe J., et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advances esophagogastric cancer. J. Clin. Oncol. 1997; 15: 261–267, [PUBMED], [INFOTRIEVE], [CSA]
  • Ross P., Nicolson M., Cunningham D., et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J. Clin. Oncol. 2002; 20: 1996–2004, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
  • Ajani J., Baker J., Pisters P., et al. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer 2002; 94: 641–646, [INFOTRIEVE], [CROSSREF], [CSA]
  • Ilson D., Saltz L., Enzinger P., et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J. Clin. Oncol. 1999; 17: 3270–3275, [INFOTRIEVE], [CSA]
  • Boku N., Ohtsu A., Shimada Y., et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J. Clin. Oncol. 1999; 17: 319–323, [INFOTRIEVE], [CSA]
  • Moiseyenko V., Ajani J., Tjulandin S., et al. Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC). Proc ASCO 2005; 23: A4002, [CSA]
  • Brambilla C., Rossi A., Bonfante V., et al. Phase II study of doxorubicin versus epirubicin in advanced breast cancer. Cancer Treat. Rep. 1986; 70: 261–266, [INFOTRIEVE], [CSA]
  • The French Epirubicin Study Group. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. J. Clin. Oncol. 1988; 6: 679–688, [CSA]
  • The Italian Multicentre Breast Study with Epirubicin. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. J. Clin. Oncol. 1988; 6: 976–982, [CSA]
  • Kaplan E., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1959; 53: 457–481, [CSA]
  • Ilson D. Epirubicin, cisplatin, and fluorouracil in gastric and esophageal cancer: a step ahead? J. Clin. Oncol. 2002; 20: 1962–1964, [CSA]
  • Levi J., Fox R., Tattersall M., Woods R., Thomson D., Gill G. Analysis of prospectively randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies. J. Clin. Oncol. 1986; 4: 1348–1355, [INFOTRIEVE], [CSA]
  • Moertel C., Lavin P. Phase II-III studies in advanced gastric cancer. Cancer Treat. Rep. 1979; 63: 1863–1869, [INFOTRIEVE], [CSA]
  • The Gastrointestinal Tumor Study Group. Phase II-III chemotherapy studies in advanced gastric cancer. Cancer Treat. Rep. 1979; 63: 1871–1876, [CSA]

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.